drugset / Trial / NCT04852523

18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

NCT04852523

Phase 0 Completed 4 enrolled University of Utah
NaSingle-groupOpen-labelDiagnostic

Summary

Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of rejection Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for pancreatic function

Timeline

Start
2021-09-16
Primary completion
2022-10-06
Completion
2022-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluciclovine Diagnostic / imaging agent